SELLAS Life Sciences Group, Inc.

NasdaqCM:SLS Stock Report

Market Cap: US$62.5m

SELLAS Life Sciences Group Balance Sheet Health

Financial Health criteria checks 4/6

SELLAS Life Sciences Group has a total shareholder equity of $15.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $26.5M and $10.6M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$21.03m
EquityUS$15.89m
Total liabilitiesUS$10.61m
Total assetsUS$26.51m

Recent financial health updates

Recent updates

Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely

Nov 23
Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Jun 18
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Jul 13
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Sep 20
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

SELLAS Life Sciences rises 9% after cancer drug shows promising result in animal study

Aug 09

We Think SELLAS Life Sciences Group (NASDAQ:SLS) Needs To Drive Business Growth Carefully

Mar 08
We Think SELLAS Life Sciences Group (NASDAQ:SLS) Needs To Drive Business Growth Carefully

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Nov 23
Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Companies Like SELLAS Life Sciences Group (NASDAQ:SLS) Are In A Position To Invest In Growth

Jul 19
Companies Like SELLAS Life Sciences Group (NASDAQ:SLS) Are In A Position To Invest In Growth

SELLAS Life Sciences updates on at-the-market offering

Jun 02

Financial Position Analysis

Short Term Liabilities: SLS's short term assets ($24.0M) exceed its short term liabilities ($10.6M).

Long Term Liabilities: SLS has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: SLS is debt free.

Reducing Debt: SLS had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SLS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SLS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9.2% each year


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:30
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SELLAS Life Sciences Group, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Li Wang WatsekCantor Fitzgerald & Co.
Joseph PantginisH.C. Wainwright & Co.